Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | HRAS | P01112 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31453291 | 1.00 | SLC7A5 (0.63) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL11440820 | 1.00 | SLC7A5 (0.63) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL4126484 | 0.99 | SLC7A5 (0.61) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL4188588 | 0.99 | SLC7A5 (0.61) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL19115126 | 0.89 | SLC7A5 (0.57) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL10694411 | 0.89 | SLC7A5 (0.57) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL28391235 | 0.89 | SLC7A5 (0.57) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL27406548 | 0.88 | SLC7A5 (0.50) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL14617681 | 0.88 | SLC7A5 (0.48) | SLC7A5PTGS1TDP1KDM4EUSP2 | |
| SCHEMBL23086058 | 0.87 | SLC7A5 (0.49) | SLC7A5PTGS1TDP1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| EP-3917504-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-112312924-A | Combination therapy by using anti-Globo H or anti-SSEA-4 antibodies with anti-negative immune checkpoint antibodies | 台湾浩鼎生技股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2020160256-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| CN-110290800-A | Conjugating biomolecules, medical composition and method | 台湾浩鼎生技股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| EP-2516387-B1 | INHIBITORS OF CYCLOPHILINS FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF VIRAL PATHOLOGIES OR INFECTIONS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE (INSERM) (FR) | 2018-02-21 | — | — | EP | disclosed |
| US-9861600-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment | Arizona Board of Regents, A Body Corporate Of The State Of Arizona Acting For An On Behalf Of The University of Arizona (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2017-07-13 | — | — | US | disclosed |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| CN-102127145-B | Substituted tetrahydroisoquinoline compound as well as preparation method and application thereof | UNIV BEIJING | 2012-07-04 | — | — | CN | disclosed |
| CN-101497651-B | Compound with thrombolytic activity, preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-06-27 | — | — | CN | disclosed |
| CN-102241740-A | Compounds with thrombolytic activities and preparation methods and applications thereof | UNIV CAPITAL MEDICAL | 2011-11-16 | — | — | CN | disclosed |
| CN-102127145-A | Substituted tetrahydroisoquinoline compound as well as preparation method and application thereof | UNIV BEIJING | 2011-07-20 | — | — | CN | disclosed |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | Arizona Board of Regents, a body Corporate of the State of Arizona, acting for and on behalf of the (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2273988-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009129497-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-22 | — | — | WO | disclosed |
| CN-101497651-A | Compound with thrombolytic activity, preparation method and application thereof | UNIV CAPITAL MEDICAL (CN) | 2009-08-05 | — | — | CN | disclosed |
| US-5686423-A | DOPAMINE PRODRUGS | DEPARTMENT OF HEALTH, THE EXECUTIVE YUAN, REPUBLIC OF CHINA (TW) | 1997-11-11 | — | — | US | disclosed |
| US-4021538-A | Method for producing pigmentation in hair or skin | YU RUEY J | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | MTNR1A, MC1R, MTNR1B | SLC7A5 761/4885PTGS1 1099/4885TDP1 3062/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | SLC7A5 761/4885PTGS1 1099/4885TDP1 3062/4885 |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | PDE6C, AGER, PDE6D | SLC7A5 4605/4885PTGS1 304/4885TDP1 1982/4885 |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | PDE6C, PDE6D, AGER | SLC7A5 4569/4885PTGS1 318/4885TDP1 2234/4885 |
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | COMT, SNCA, SCLY | SLC7A5 139/4885PTGS1 1835/4885TDP1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.